Product Program year 2025 Source: CMS Open Payments

Arcalyst

Drug Not Applicable

NDC 73604-914-01

Open in the dashboard

General payments

$913,516

32,707 payments

Research payments

$1,263,456

76 payments

Through program year 2025, $913,516 in general payments and $1,263,456 in research payments were reported against Arcalyst (Not Applicable).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2025 Research $816,517 13
2024 General $626,199 20,859
2023 General $279,717 11,845
2022 General $7,600 3
2022 Research $446,940 63

Breakdown

Who paid General payments · program years 2022–2024
  1. Kiniksa Pharmaceuticals International, plc $626,199 20,859 payments
  2. Kiniksa Pharmaceuticals, Ltd. $287,317 11,848 payments
Top recipients General payments · program year 2024
  1. Beth Israel Deaconess Medical Center Teaching hospital · MA $126,760 20% · 10 payments
  2. Dhanunjaya Lakkireddy Clinical Cardiac Electrophysiology · Kansas City, KS $13,400 2% · 1 payment
  3. Paul Cremer Cardiovascular Disease · Chicago, IL $11,952 2% · 3 payments
  4. Michael Allen Rheumatology · Troy, NY $4,476 <1% · 5 payments
  5. Antonio Abbate Cardiovascular Disease · Charlottesville, VA $3,219 <1% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Cardiovascular Disease Internal Medicine $177,844 36% · 3,324 practitioners
  2. Interventional Cardiology Internal Medicine $54,945 11% · 1,316 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $47,465 10% · 1,162 practitioners
  4. Rheumatology Internal Medicine $35,284 7% · 706 practitioners
  5. Physician Assistant $32,026 7% · 734 practitioners

The top 5 of 88 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Massachusetts $138,557 22% · 165 recipients
  2. California $68,889 11% · 1,121 recipients
  3. New York $54,419 9% · 974 recipients
  4. Florida $45,191 7% · 1,063 recipients
  5. Texas $29,188 5% · 781 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,240

Prescriptions dispensed, refills included

Drug cost

$28,486,994

Paid at the pharmacy, in all

Prescribers

76

With 11 or more claims of it

Medicare Part D drugs matched to Arcalyst, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Arcalyst Rilonacept Same name 76 1,240 $28,486,994

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 76 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Mary Heine Nurse Practitioner OH 76 $1,671,543 $273
Jonathan Salik Internal Medicine MA 58 $1,568,450 $251
Michael Garshick Cardiology NY 54 $1,219,551 $281
Tracy Hagerty Cardiology MA 40 $930,557 $125
Allan Klein Cardiology OH 29 $659,060 $216

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 76 with Patron
32,707 general · 76 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record